A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by ...

( MENAFN - Mid-East Info) Interstitial Lung disease Summit 2024 brings together more than 140 healthcare professionals from ...

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on ...

Dr Tim Oldham unpacks what IPF is, who it impacts, and what the company is doing in the fight against it with AD-214.

Avalyn has initiated a Phase 1b study for its second program, AP02, inhaled nintedanib, that is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). For more information, please ...

According to a ... Researchers Identify Protein Connected to Aging and Idiopathic Pulmonary Fibrosis July 25, 2022 — Idiopathic pulmonary fibrosis (IPF) is an aging-associated disease caused by ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that ...